← Leaderboards
Van K Morris
University Of Tx Md Anderson Can Ctr
$363,280
Attributed
$363,280
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $181.6K · FY2024–25$200K$150K$100K$50K$0
'24
'25
Funding mix
By agency
NIH$363,280 · 1
By mechanism
R50$363,280 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Tx Md Anderson Can Ctr
Same institution · by research overlap
- Scott Kopetz$13,199,822
- James C Yao$2,907,879
- Prasenjit Dey$3,083,364
- Eduardo Vilar Sanchez$16,310,319
- Laszlo George Radvanyi$2,629,361
Others in their field
Other Rising Stars on “Adjuvant Chemotherapy”
- Kathryn Marie Jones · Baylor College Of Medicine$3,103,804
- Amy Fowler · University Of Wisconsin-Madison$3,008,001
- Alice Chia- Chi Wei · Sloan-Kettering Inst Can Research$2,617,533
- Nadine Norton · Mayo Clinic Jacksonville$2,431,858
- Moustafa Gabr · Weill Medical Coll Of Cornell Univ$2,101,095
- Nduka Mgbechinyere Amankulor · University Of Pennsylvania$2,082,285
Research focus
Adjuvant ChemotherapyBiopsy SpecimenBiological MarkersBlood-Based BiomarkerCancer CenterCetuximabBloodClinical TrialsClinical Trials DesignColon CarcinomaColorectal CancerCombination ImmunotherapyDesignDetection Of Minimal Residual DiseaseEarly Therapeutic-Clinical Trials NetworkEnrollmentFundingFutureGenomicsGrantGuidelinesHands-On LearningHeadImmunotherapy
Grant awards (2)
Multi-omic liquid biopsy assessment in NCI trials: evaluating ctDNA, extravesicle RNA, and outcomes with immunotherapy in patient with colorectal and anal cancers$181,640
R50 · FY2025 · CA · contact PI
Multi-omic liquid biopsy assessment in NCI trials: evaluating ctDNA, extravesicle RNA, and outcomes with immunotherapy in patient with colorectal and anal cancers$181,640
R50 · FY2024 · CA · contact PI